全文获取类型
收费全文 | 94059篇 |
免费 | 6381篇 |
国内免费 | 287篇 |
专业分类
耳鼻咽喉 | 1167篇 |
儿科学 | 2436篇 |
妇产科学 | 2155篇 |
基础医学 | 16187篇 |
口腔科学 | 2402篇 |
临床医学 | 8388篇 |
内科学 | 18383篇 |
皮肤病学 | 1811篇 |
神经病学 | 9160篇 |
特种医学 | 3993篇 |
外国民族医学 | 45篇 |
外科学 | 12568篇 |
综合类 | 672篇 |
一般理论 | 97篇 |
预防医学 | 6419篇 |
眼科学 | 1907篇 |
药学 | 6838篇 |
中国医学 | 182篇 |
肿瘤学 | 5917篇 |
出版年
2021年 | 1192篇 |
2020年 | 926篇 |
2019年 | 1387篇 |
2018年 | 1667篇 |
2017年 | 1204篇 |
2016年 | 1459篇 |
2015年 | 1707篇 |
2014年 | 2093篇 |
2013年 | 3448篇 |
2012年 | 4550篇 |
2011年 | 4765篇 |
2010年 | 3354篇 |
2009年 | 2947篇 |
2008年 | 4606篇 |
2007年 | 4798篇 |
2006年 | 4653篇 |
2005年 | 4620篇 |
2004年 | 4559篇 |
2003年 | 4276篇 |
2002年 | 4386篇 |
2001年 | 2448篇 |
2000年 | 2403篇 |
1999年 | 2264篇 |
1998年 | 1160篇 |
1997年 | 981篇 |
1996年 | 844篇 |
1995年 | 974篇 |
1994年 | 826篇 |
1993年 | 837篇 |
1992年 | 1640篇 |
1991年 | 1590篇 |
1990年 | 1495篇 |
1989年 | 1475篇 |
1988年 | 1262篇 |
1987年 | 1231篇 |
1986年 | 1165篇 |
1985年 | 1113篇 |
1984年 | 868篇 |
1983年 | 804篇 |
1982年 | 646篇 |
1981年 | 606篇 |
1980年 | 503篇 |
1979年 | 719篇 |
1978年 | 506篇 |
1977年 | 475篇 |
1976年 | 415篇 |
1975年 | 460篇 |
1974年 | 505篇 |
1973年 | 436篇 |
1972年 | 423篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
5.
European Journal of Epidemiology - Existing research has found adverse short-term effects of the COVID-19 pandemic on mental health, but longer-term effects have been less documented. Using newly... 相似文献
6.
7.
8.
Bielik Peter Bonczek Ondřej Krejčí Přemysl Zeman Tomáš Izakovičová-Hollá Lydie Šoukalová Jana Vaněk Jiří Vojtěšek Bořivoj Lochman Jan Balcar Vladimir J. Šerý Omar 《Clinical oral investigations》2022,26(12):7045-7055
Clinical Oral Investigations - The aim of this study was the analysis of WNT10A variants in seven families of probands with various forms of tooth agenesis and self-reported family history of... 相似文献
9.
ABSTRACTThe average amount of sleep people of all ages get has declined sharply in the past 50 years. The detrimental health effects of sleep deprivation are well documented and substantial. Even though electronic media use often takes place in the hours before sleep, the extent to which media use may interact with sleep is understudied and not well understood. Communication scholars are well positioned to contribute to this area, as a systematic, theoretical understanding of the relationship between media and sleep is still lacking. This primer charts the state of knowledge on electronic media and sleep and explores possible next steps. First, we introduce the problem of sleep deprivation and describe the basic science of sleep with relevant terminology. Then, we review the research on electronic media and sleep and offer an agenda for research. 相似文献
10.
Mieke R. Van Bockstal Marie C. Agahozo Linetta B. Koppert Carolien H.M. van Deurzen 《International journal of cancer. Journal international du cancer》2020,146(5):1189-1197
Ductal carcinoma in situ (DCIS) of the breast is a nonobligate precursor of invasive breast cancer, accounting for 20 % of screen-detected breast cancers. Little is known about the natural progression of DCIS because most patients undergo surgery upon diagnosis. Many DCIS patients are likely being overtreated, as it is believed that only around 50 % of DCIS will progress to invasive carcinoma. Robust prognostic markers for progression to invasive carcinoma are lacking. In the past, studies have investigated women who developed a recurrence after breast-conserving surgery (BCS) and compared them with those who did not. However, where there is no recurrence, the patient has probably been adequately treated. The present narrative review advocates a new research strategy, wherein only those patients with a recurrence are studied. Approximately half of the recurrences are invasive cancers, and half are DCIS. So-called “recurrences” are probably most often the result of residual disease. The new approach allows us to ask: why did some residual DCIS evolve to invasive cancers and others not? This novel strategy compares the group of patients that developed in situ recurrence with the group of patients that developed invasive recurrence after BCS. The differences between these groups could then be used to develop a robust risk stratification tool. This tool should estimate the risk of synchronous and metachronous invasive carcinoma when DCIS is diagnosed in a biopsy. Identification of DCIS patients at low risk for developing invasive carcinoma will individualize future therapy and prevent overtreatment. 相似文献